These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 26524472)
1. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities. Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472 [TBL] [Abstract][Full Text] [Related]
2. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands. Mosberg HI; Yeomans L; Harland AA; Bender AM; Sobczyk-Kojiro K; Anand JP; Clark MJ; Jutkiewicz EM; Traynor JR J Med Chem; 2013 Mar; 56(5):2139-49. PubMed ID: 23419026 [TBL] [Abstract][Full Text] [Related]
3. Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands. Healy JR; Bezawada P; Griggs NW; Devereaux AL; Matsumoto RR; Traynor JR; Coop A; Cunningham CW Bioorg Med Chem Lett; 2017 Feb; 27(3):666-669. PubMed ID: 28011222 [TBL] [Abstract][Full Text] [Related]
4. Development of novel LP1-based analogues with enhanced delta opioid receptor profile. Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666 [TBL] [Abstract][Full Text] [Related]
5. Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands. Harland AA; Bender AM; Griggs NW; Gao C; Anand JP; Pogozheva ID; Traynor JR; Jutkiewicz EM; Mosberg HI J Med Chem; 2016 May; 59(10):4985-98. PubMed ID: 27148755 [TBL] [Abstract][Full Text] [Related]
6. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands. Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166 [TBL] [Abstract][Full Text] [Related]
7. Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors. Eans SO; Ganno ML; Mizrachi E; Houghten RA; Dooley CT; McLaughlin JP; Nefzi A J Med Chem; 2015 Jun; 58(12):4905-17. PubMed ID: 25996309 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors. Neumeyer JL; Zhang B; Zhang T; Sromek AW; Knapp BI; Cohen DJ; Bidlack JM J Med Chem; 2012 Apr; 55(8):3878-90. PubMed ID: 22439881 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists. Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782 [TBL] [Abstract][Full Text] [Related]
10. Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide. Purington LC; Sobczyk-Kojiro K; Pogozheva ID; Traynor JR; Mosberg HI ACS Chem Biol; 2011 Dec; 6(12):1375-81. PubMed ID: 21958158 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands. Bender AM; Clark MJ; Agius MP; Traynor JR; Mosberg HI Bioorg Med Chem Lett; 2014 Jan; 24(2):548-51. PubMed ID: 24365161 [TBL] [Abstract][Full Text] [Related]
12. Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective kappa-opioid receptor antagonist. Chauvignac C; Miller CN; Srivastava SK; Lewis JW; Husbands SM; Traynor JR J Med Chem; 2005 Mar; 48(5):1676-9. PubMed ID: 15743210 [TBL] [Abstract][Full Text] [Related]
13. Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models. Anand JP; Purington LC; Pogozheva ID; Traynor JR; Mosberg HI Chem Biol Drug Des; 2012 Nov; 80(5):763-70. PubMed ID: 22882801 [TBL] [Abstract][Full Text] [Related]
14. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring. Rennison D; Moynihan H; Traynor JR; Lewis JW; Husbands SM J Med Chem; 2006 Oct; 49(20):6104-10. PubMed ID: 17004724 [TBL] [Abstract][Full Text] [Related]
15. Ex vivo delta opioid receptor autoradiography: CNS receptor occupancy of two novel compounds over their antihyperalgesic dose range. Codd EE; Ma J; Zhang SP; Stone DJ; Colburn RW; Brandt MR; Chevalier KM; Zhu Y; Peng S; Cai C; Acton PD; Flores CM Pharmacol Biochem Behav; 2010 Aug; 96(2):130-5. PubMed ID: 20438745 [TBL] [Abstract][Full Text] [Related]
16. Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy. Harland AA; Pogozheva ID; Griggs NW; Trask TJ; Traynor JR; Mosberg HI ACS Chem Neurosci; 2017 Nov; 8(11):2549-2557. PubMed ID: 28796483 [TBL] [Abstract][Full Text] [Related]
17. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors. Olianas MC; Concas D; Onali P Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δ opioid receptor agonist and δ opioid receptor antagonist activities. Hu M; Giulianotti MA; McLaughlin JP; Shao J; Debevec G; Maida LE; Geer P; Cazares M; Misler J; Li L; Dooley C; Ganno ML; Eans SO; Mizrachi E; Santos RG; Yongye AB; Houghten RA; Yu Y Eur J Med Chem; 2015 Mar; 92():270-81. PubMed ID: 25559207 [TBL] [Abstract][Full Text] [Related]
19. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist. Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957 [TBL] [Abstract][Full Text] [Related]
20. Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan. Srivastava SK; Shefali S; Miller CN; Aceto MD; Traynor JR; Lewis JW; Husbands SM J Med Chem; 2004 Dec; 47(26):6645-8. PubMed ID: 15588100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]